Celularity Inc., a clinical-stage biotechnology company, released its financial results for the quarter ending March 31, 2025. The company reported its financial performance with a focus on its three business segments: Cell Therapy, Degenerative Disease, and BioBanking. The report highlights that Celularity has not generated revenue from the sale of cellular therapies, as it continues to invest substantially in research and development activities, including pre-clinical studies and clinical development of cell programs. These investments have been funded through limited revenues and have impacted the company's short-term profitability. The company continues to operate as a going concern, relying on its ability to realize assets and settle liabilities in the normal course of business. Celularity's management is focused on advancing its cellular therapy programs, which remain unproven and in various phases of development. The company's outlook emphasizes the inherent risks and uncertainties associated with the development of its enterprise, including the challenges of achieving regulatory success in clinical trials and the potential for treating patients with its therapies once commercial status is achieved.